Monoclonal antibody G250 recognizes a determinant present in renal-cell carcinoma and absent from normal kidney
Oosterwijk E, Ruiter DJ, Hoedemaeker PJ et al. Monoclonal antibody G250 recognizes a determinant present in renal-cell carcinoma and absent from normal kidney. Int J Cancer 1986 38 : 489 94
Cloning and characterization of MN, a human tumor-associated protein with a domain homologous to carbonic anhydrase and a putative helix-loop-helix DNA binding segment
Pastorek J, Pastorekova S, Callebaut I et al. Cloning and characterization of MN, a human tumor-associated protein with a domain homologous to carbonic anhydrase and a putative helix-loop-helix DNA binding segment. Oncogene 1994 9 : 2877 88
Molecular cloning and immunogenicity of renal cell carcinoma-associated antigen G250
Grabmaier K, Vissers JL, De Weijert MC et al. Molecular cloning and immunogenicity of renal cell carcinoma-associated antigen G250. Int J Cancer 2000 85 : 865 70
Genetics of renal-cell carcinoma and evidence for a critical role for von Hippel-Lindau in renal tumorigenesis
Gnarra JR, Lerman MI, Zbar B, Linehan WM. Genetics of renal-cell carcinoma and evidence for a critical role for von Hippel-Lindau in renal tumorigenesis. Semin Oncol 1995 22 : 3 8
Prognostic value of carbonic anhydrase IX and KI67 as predictors of survival for renal clear cell carcinoma
Bui MH, Visapaa H, Seligson D et al. Prognostic value of carbonic anhydrase IX and KI67 as predictors of survival for renal clear cell carcinoma. J Urol 2004 171 : 2461 6
Carbonic anhydrase IX is an independent predictor of survival in advanced renal clear cell carcinoma: Implications for prognosis and therapy
Bui MH, Seligson D, Han KR et al. Carbonic anhydrase IX is an independent predictor of survival in advanced renal clear cell carcinoma: implications for prognosis and therapy. Clin Cancer Res 2003 9 : 802 11
Carbonic anhydrase IX expression predicts outcome of interleukin 2 therapy for renal cancer
Atkins M, Regan M, McDermott D et al. Carbonic anhydrase IX expression predicts outcome of interleukin 2 therapy for renal cancer. Clin Cancer Res 2005 11 : 3714 21
Antibody localization in human renal cell carcinoma: A phase I study of monoclonal antibody G250
Oosterwijk E, Bander NH, Divgi CR et al. Antibody localization in human renal cell carcinoma: a phase I study of monoclonal antibody G250. J Clin Oncol 1993 11 : 738 50
Preoperative characterisation of clear-cell renal carcinoma using iodine-124-labelled antibody chimeric G250 (124I-cG250) and PET in patients with renal masses: A phase I trial
Divgi CR, Pandit-Taskar N, Jungbluth AA et al. Preoperative characterisation of clear-cell renal carcinoma using iodine-124-labelled antibody chimeric G250 (124I-cG250) and PET in patients with renal masses: a phase I trial. Lancet Oncol 2007 8 : 304 10